Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | BHMT | Q93088 | 1/20 | 0.37 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7985448 | 0.84 | MAPT (0.40) | MAPTGMNNTP53POLBTHRB | |
| SCHEMBL13461104 | 0.83 | CES2 (0.50) | MAPTGMNNTP53POLBTHRB | |
| SCHEMBL9522178 | 0.83 | MAPT (0.38) | MAPTGMNNTP53POLBTHRB | |
| SCHEMBL16727727 | 0.81 | GMNN (0.48) | MAPTGMNNTP53POLBTHRB | |
| SCHEMBL1504096 | 0.80 | TDP1 (0.56) | MAPTGMNNTP53POLBTHRB | |
| SCHEMBL679006 | 0.78 | CES1 (0.39) | MAPTCHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL29193673 | 0.78 | KDM1A (0.35) | MAPTHSD17B10CYP2D6CHRM2CHRM4 | |
| SCHEMBL9525485 | 0.77 | CYP2D6 (0.50) | MAPTGMNNTP53POLBTHRB | |
| Hydrochloric Acid SCHEMBL14157523 | 0.76 | CYP2D6 (0.48) | MAPTGMNNTP53POLBTHRB | |
| SCHEMBL950901 | 0.75 | SLC2A1 (0.37) | MAPTPOLBCHRM2CHRM4CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110003066-A | Ionizable cation lipid for RNA delivery | 阿克丘勒斯治疗公司 | 2019-07-12 | — | — | CN | claimed |
| US-RE50681-E1 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250304532-A1 | METHOD OF SYNTHESIS OF AN IONIZABLE CATIONIC LIPID | ARCTURUS THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| US-12286395-B2 | Method of synthesis of an ionizable cationic lipid | ARCTURUS THERAPEUTICS, INC. (US) | 2025-04-29 | — | — | US | disclosed |
| EP-3071547-B1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-117480151-A | Purification method of pleuromutilin | 礼蓝动物保健有限公司 | 2024-01-30 | — | — | CN | disclosed |
| US-20230265040-A1 | PROCESS FOR PURIFICATION OF PLEUROMUTILINS | ELANCO TIERGESUNDHEIT AG (CH) | 2023-08-24 | — | — | US | disclosed |
| EP-3221293-B1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS INC (US) | 2023-03-01 | — | — | EP | disclosed |
| US-RE49233-E1 | Ionizable cationic lipid for RNA delivery | ARCTURUS THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2022094247-A1 | PROCESS FOR PURIFICATION OF PLEUROMUTILINS | ELANCO TIERGESUNDHEIT AG (CH) | 2022-05-05 | — | — | WO | disclosed |
| US-20150239834-A1 | SYMMETRIC IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150141678-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141678-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150141678-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | ARCTURUS THERAPEUTICS, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20120010281-A1 | ANTIMICROBIAL AND ANTITUBERCULAR COMPOUNDS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-01-12 | — | — | US | disclosed |
| EP-0226896-B1 | LANKACIDIN DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-4914206-A | ANTIBIOTICS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-04-03 | — | — | US | disclosed |
| EP-0226896-A2 | Lankacidin derivatives and production thereof | Takeda Chemical Industries, Ltd. (JP) | 1987-07-01 | — | — | EP | disclosed |
| US-4422945-A | WATER TREATMENT, HYPOCHLORITE SCAVENGER | E. R. SQUIBB & SONS, INC. (US) | 1983-12-27 | — | — | US | disclosed |
| US-4390558-A | USING SCABENGERS | E. R. SQUIBB & SONS, INC. (US) | 1983-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230265040-A1 | PROCESS FOR PURIFICATION OF PLEUROMUTILINS | PLEC, MLN, MLNR | MAPT 4442/4885GMNN 1306/4885TP53 2211/4885 |
| US-12286395-B2 | Method of synthesis of an ionizable cationic lipid | SGMS1, SGMS2, LIPA | MAPT 4672/4885GMNN 2627/4885TP53 4847/4885 |
| US-20250304532-A1 | METHOD OF SYNTHESIS OF AN IONIZABLE CATIONIC LIPID | SGMS1, SGMS2, LIPA | MAPT 4672/4885GMNN 2627/4885TP53 4847/4885 |
| US-20150239834-A1 | SYMMETRIC IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | POLR2H, POLR2E, RNASEH1 | MAPT 4334/4885GMNN 2046/4885TP53 3894/4885 |
| US-20150141678-A1 | IONIZABLE CATIONIC LIPID FOR RNA DELIVERY | NSUN3, RNASEH1, NPC1L1 | MAPT 4229/4885GMNN 3289/4885TP53 3874/4885 |
| US-20120010281-A1 | ANTIMICROBIAL AND ANTITUBERCULAR COMPOUNDS | TBK1, TBCD, TBKBP1 | MAPT 642/4885GMNN 3720/4885TP53 1180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.